477 related articles for article (PubMed ID: 15730050)
1. Recombinant human erythropoietin independence in chronic hemodialysis patients: clinical features, iron homeostasis and erythropoiesis.
Kuo CC; Lee CT; Chuang CH; Su Y; Chen JB
Clin Nephrol; 2005 Feb; 63(2):92-7. PubMed ID: 15730050
[TBL] [Abstract][Full Text] [Related]
2. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients.
Chiang WC; Tsai TJ; Chen YM; Lin SL; Hsieh BS
Clin Nephrol; 2002 Nov; 58(5):363-9. PubMed ID: 12425487
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and related factors of the absence of anemia among Chinese chronic hemodialysis patients: a multicenter cross-sectional study.
Wan Q; He Y; Zhang W; Wu Q; Xiong Z
Int Urol Nephrol; 2014 Aug; 46(8):1651-4. PubMed ID: 24114285
[TBL] [Abstract][Full Text] [Related]
4. Determinants of circulating soluble transferrin receptor level in chronic haemodialysis patients.
Tarng DC; Huang TP
Nephrol Dial Transplant; 2002 Jun; 17(6):1063-9. PubMed ID: 12032198
[TBL] [Abstract][Full Text] [Related]
5. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.
Gaweda AE; Goldsmith LJ; Brier ME; Aronoff GR
Clin J Am Soc Nephrol; 2010 Apr; 5(4):576-81. PubMed ID: 20110344
[TBL] [Abstract][Full Text] [Related]
6. Effects of parathyroidectomy on iron homeostasis and erythropoiesis in hemodialysis patients with severe hyperparathyroidism.
Lee CT; Chou FF; Chang HW; Hsu YH; Lee WC; Liao SC; Chen JB
Blood Purif; 2003; 21(6):369-75. PubMed ID: 14586178
[TBL] [Abstract][Full Text] [Related]
7. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
8. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability of iron in hemodialysis patients treated with erythropoietin: evidence for the inhibitory role of aluminum.
Donnelly SM; Ali MA; Churchill DN
Am J Kidney Dis; 1990 Nov; 16(5):447-51. PubMed ID: 2239935
[TBL] [Abstract][Full Text] [Related]
10. Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients.
Belo L; Rocha S; Valente MJ; Coimbra S; Catarino C; Bronze-da-Rocha E; Rocha-Pereira P; do Sameiro-Faria M; Oliveira JG; Madureira J; Fernandes JC; Miranda V; Santos-Silva A
Ren Fail; 2019 Nov; 41(1):662-672. PubMed ID: 31296086
[No Abstract] [Full Text] [Related]
11. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
12. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
13. Variation of clinical and laboratory features in chronic dialysis patients treated with high-flux hemodialysis after switching to online hemodiafiltration.
Orasan RA; Patiu IM; Anghel D; Bejan C; Iosub L; Totolici C; Pop M; Turcea C; Teodoru C; Orasan OH; Kacso IM; Gherman Caprioara M
Int Urol Nephrol; 2013 Oct; 45(5):1415-22. PubMed ID: 23212146
[TBL] [Abstract][Full Text] [Related]
14. Predictors of erythropoietin responsiveness in chronic hemodialysis patients.
Tonelli M; Blake PG; Muirhead N
ASAIO J; 2001; 47(1):82-5. PubMed ID: 11199321
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of reticulocyte hemoglobin content, percentage of hypochromic red blood cells, and ratio of serum transferrin receptor level/serum iron level as markers of iron-deficiency erythropoiesis in patients undergoing hemodialysis].
Hasegawa M; Kawamura N; Koide S; Murase M; Asano S; Toba T; Kushimoto H; Murakami K; Tomita M; Hasegawa H; Shikano M; Mizuno M; Funahashi N; Kawashima S; Sugiyama S
Nihon Jinzo Gakkai Shi; 2002; 44(5):453-63. PubMed ID: 12216478
[TBL] [Abstract][Full Text] [Related]
16. Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients.
Abe M; Okada K; Soma M; Matsumoto K
Clin Nephrol; 2011 Jan; 75(1):49-58. PubMed ID: 21176750
[TBL] [Abstract][Full Text] [Related]
17. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
Zehnder C; Blumberg A
Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure.
Aucella F; Vigilante M; Scalzulli P; Musto P; Prencipe M; Valente GL; Carotenuto M; Stallone C
Nephrol Dial Transplant; 1999 May; 14(5):1171-5. PubMed ID: 10344357
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
[TBL] [Abstract][Full Text] [Related]
20. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
Frankenfield DL; Johnson CA
Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
